Relmada rails against depression data both 'implausible' and 'unplausible' in latest phase 3 flunk

Relmada Therapeutics’ REL-1017 has failed another phase 3 depression clinical trial. And, like last time, the biotech has blamed everything but the drug candidate, pinning the failures on “a limited number of high enrolling sites with unplausible placebo response.”